Arab Therapy closes $2 million pre-Series A funding round
Arab TherapyCompany
Manara VenturesInvestor
Arab Therapy closed a $2 million pre‑Series A round on Aug. 11, 2026, led by Manara Ventures with participation from Anara Impact Fund and Value Makers Studio, to fund expansion across Saudi Arabia and the broader Middle East.
Arab Therapy closed a $2 million pre‑Series A funding round on Aug. 11, 2026, led by Manara Ventures with participation from Anara Impact Fund and Value Makers Studio. The Berlin‑based startup, founded in 2021 by Dr Tareq Dalbah and Hekmat Al Hasi, will deploy the capital to accelerate its go‑to‑market push in Saudi Arabia and neighboring markets.
The company delivers an Arabic‑language mental‑health platform that blends online therapy sessions with licensed clinicians, a curated content library, and AI‑driven assessment tools. Its dual‑track model serves individual users (B2C) and corporate wellness programs (B2B), positioning the business as a vertical SaaS solution for a linguistically underserved segment of more than 400 million Arabic speakers.
Deal Terms
The $2 million raise follows a $1 million seed round in April 2024 that was led by Flat6Labs and Vision Health Pioneers. While the round’s valuation and ARR multiples were not disclosed, the participation of Manara Ventures—a fund focused on early‑stage health‑tech—signals confidence in Arab Therapy’s growth trajectory. Anara Impact Fund and Value Makers Studio added strategic capital, broadening the investor base beyond traditional venture capital.
Strategic Rationale
Expansion into Saudi Arabia targets a market with high internet penetration and growing corporate investment in employee mental‑wellness. The funding will support hiring of additional Arabic‑speaking clinicians, scaling of AI algorithms, and localized compliance efforts. By leveraging AI to triage and personalize care, Arab Therapy aims to reduce therapist time per client, a lever that can improve gross margins as the company scales.
The pre‑Series A also positions Arab Therapy to capture market share from generic global mental‑health platforms that lack Arabic language support. With a culturally attuned clinical framework overseen by University of Hamburg experts, the startup can differentiate on both linguistic relevance and regulatory compliance, key factors for enterprise contracts in the region.
Overall, the round equips Arab Therapy to transition from a seed‑stage product to a growth‑stage SaaS business, with the potential to generate recurring revenue streams from subscription‑based B2C users and multi‑year enterprise licenses.
Why It Matters
Arab Therapy’s new capital enables rapid headcount expansion and AI refinement, giving it a timing advantage over regional rivals that are still building Arabic‑language content pipelines. For existing competitors such as Mindful Arabic and regional tele‑health providers, the infusion of venture capital may force accelerated product roadmaps and pricing pressure as Arab Therapy pursues enterprise contracts with large Saudi corporations.
Manara Ventures and its co‑investors gain a foothold in a high‑growth health‑tech niche, complementing their portfolios with a vertical SaaS play that can be scaled across the GCC. Their involvement also signals to other investors that Arabic‑language digital health is a viable segment, potentially unlocking additional funding for peers and new entrants.
The round reinforces the broader trend of AI‑enabled mental‑health platforms moving beyond English‑centric markets, prompting operators to consider language‑specific compliance and cultural adaptation as core components of their GTM strategies.
Key Points
- Arab Therapy raised $2 million in a pre‑Series A round on Aug. 11, 2026.
- The round was led by Manara Ventures with participation from Anara Impact Fund and Value Makers Studio.
- Funding will be used to expand the AI‑powered mental‑health platform in Saudi Arabia and the wider Middle East.
- Arab Therapy serves both B2C users and B2B corporate wellness clients with Arabic‑language therapy and AI tools.
- The company previously closed a $1 million seed round in April 2024.
Analysis
The $2 million raise places Arab Therapy at a valuation tier where typical health‑tech SaaS multiples range between 8‑12 x forward‑looking ARR, depending on churn and gross margin profiles. Assuming a modest ARR of $1 million post‑seed, the round could imply a valuation near $8‑12 million, a range that aligns with other early‑stage AI‑enabled mental‑health firms in emerging markets. The infusion of capital will likely accelerate user acquisition and enterprise sales, driving net revenue retention above 120 % as corporate contracts add multi‑year stickiness.
From an investor perspective, the deal underscores growing appetite for vertical SaaS solutions that combine AI with culturally specific content. As mental‑health spending in the GCC is projected to exceed $1 billion by 2028, platforms that can demonstrate regulatory compliance and language relevance are poised for premium multiples. Operators will need to balance rapid scaling with maintaining clinical quality, a challenge that AI can help mitigate by automating triage and outcome tracking.
For the broader SaaS ecosystem, Arab Therapy’s round highlights a shift toward niche language markets that have been overlooked by global players. Companies that can replicate this model—leveraging AI to lower service costs while delivering localized experiences—may attract similar funding, driving consolidation and specialization within health‑tech SaaS. Investors should monitor the company’s ability to convert AI‑driven efficiencies into higher gross margins, a key lever for future Series B valuations.